Millions Logo
home>US Stocks>Merck & Co
MRK
Merck & CoHealthcare
$147.72+$56.27 (+61.53%)in 1 year
As on 14 Nov 2026 at 02:29NYSE
52 Week Low: $90.9052 Week High: $156.92

Merck & Co Share Price Today

Merck & Co opened higher at $147.31, compared with its previous close of $146.95. In the last trading session, the stock traded between $145.24 and $147.99. It showed a sideways intraday trend.

Return calculator

Time Period

An investment of $100 made 5 years ago in Merck & Co is now worth

$ 175.86

Giving a profit of

$ 75.86 (75.86%)

Invest with $1

Note: Past profits do not guarantee future returns.

Analyst Overview

Buy

Rating from 22 Analysts

Buy
68.18%
Hold
31.82%
Sell
0%

Markets Today

Today's Change

+$0.77 (+0.52%)

Day High

$147.99

Day Low

$145.24

Day Open

$147.31

Prev Close

$146.95

Volume

40,44,285

1W Return

0.68%

1M Return

1.55%

3M Return

11.13%

6M Return

31.46%

1Y Return

61.53%

Fundamentals

Market Cap ($ Mn)

3,64,169

PE Ratio

149.25

PB Ratio

8.12

PEG Ratio

11.06

ROE

36.81%

ROCE

23.02%

EPS (TTM)

$2.05

Investment Returns

1 Week

0.68%

1 Month

1.55%

3 Months

11.13%

6 Months

31.46%

9 Months

23.89%

Financials

Quarterly
All values in $ Mn
15.8K

Jun 25
17.3K

Sep 25
16.4K

Dec 25
16.3K

Mar 26
16.6K

Jun 26
18.1K

Sep 26

Updates

20Oct

Merck withdraws Zinplava from Europe after commercial review

Merck & Co Inc permanently discontinues Zinplava in Europe for commercial reasons. European Commission withdrew marketing authorization on Tuesday following holder request. The move follows the therapy's discontinuation in the United States in December 2024. Zinplava was approved for preventing recurrent Clostridium difficile infection.

25 days ago
13Oct

Merck & Co elects Paul J. Diaz to board effective Nov 2026

Paul J. Diaz joins Merck's board effective November 1, 2026. Board size increases to 14 members with this addition. Diaz stands for shareholder election in May 2027. He is managing partner at Cressey & Company.

1mo ago
13Oct

Citigroup raises Merck price target to $145, maintains neutral

Citigroup raises Merck & Co price target from $125 to $145. Analyst Geoff Meacham maintains a Neutral rating on the stock. The revised target represents a 16% increase over the previous level.

1mo ago
1Oct

Merck’s tulisokibart meets Phase 2b endpoints in skin therapy trial

Tulisokibart met primary endpoint HiSCR50 at week 16 in Phase 2b hidradenitis suppurativa trial. High-dose group achieved 72% response rate, a 37% improvement over placebo. Safety profile comparable to placebo with no serious opportunistic infections reported. Low-dose cohort showed clinical efficacy but no improvement in quality of life scores.

1mo ago
28Sep

Merck and Daiichi Sankyo withdraw FDA application for lung cancer drug

Merck and Daiichi Sankyo withdrew the BLA for ifinatamab deruxtecan after FDA feedback on accelerated approval criteria. Phase 2 trial showed a confirmed objective response rate of 48.2% in 137 patients with previously treated ES-SCLC. Median overall survival was 10.3 months, while median progression-free survival was 4.9 months. Merck entered a $2.13 billion potential value license agreement with SciBrunch Therapeutics for SPR2015. The upfront payment to SciBrunch is $400 million, resulting in a Q3FY26 pre-tax charge for Merck.

1mo ago
28Sep

Merck signs $2.13 billion deal for SciBrunch's SPR2015 inhibitor

Merck acquires global rights to SPR2015, an oral KRAS G12D inhibitor, from SciBrunch. Upfront payment of $400 million recorded as pre-tax charge in Q3 2026. Total potential deal value reaches $2.13 billion including milestone payments. SPR2015 shows antitumor efficacy in preclinical models targeting mutant KRAS.

1mo ago

Similar Stocks

StockLTPChange %Market CapPE
$1,443.72+1.40%$13,41,079.03M46.85
$285.89+0.83%$6,82,520.53M43.36
$295.06+0.21%$5,20,474.53M50.69
$160.51+0.16%$3,26,079.91M30.63
$184.50+0.06%$2,85,985.36M26.09
$465.65-0.30%$2,52,637.89M27.00
$168.04+0.05%$2,08,314.94M-
$28.90+0.23%$1,64,326.79M41.27
$41.64+2.43%$1,37,808.70M10.50
$63.42+1.77%$1,27,387.44M14.06
$48.36-0.21%$1,17,057.36M24.06
$50.47+1.44%$1,01,516.65M17.60